CMS Announces Phase 3 Success of Ruxolitinib Cream in Atopic Dermatitis
China Medical System Holdings Limited (CMS, HKG: 0867) reported that its Phase 3, randomized, double‑blind, placebo‑controlled...
Incyte Pharmaceuticals
China Medical System’s Opzelura Approved in Hong Kong for Non-segmental Vitiligo Treatment
China Medical System Holdings (CMS; HKG: 0867) has announced that the market filing for its...
China Medical System’s Opzelura Cream Filing for Vitiligo Accepted by NMPA
China Medical System Holdings (CMS; HKG: 0867) has announced that its market filing for Opzelura...
China Medical System’s Opzelura Approved in Macau for Vitiligo Treatment
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received market approval...
China Medical System Expands Portfolio with Incyte’s Povorcitinib for Autoimmune Diseases
China Medical System Holdings (CMS; HKG: 0867) has announced a new cooperation and licensing agreement...
3D Medicines’ 3D185 Receives Orphan Drug Designation for Gastric Cancer
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving orphan drug designation (ODD) status...
China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia
China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...
Innovent’s Parsaclisib Filed for Marketing Approval in China
China’s Center for Drug Evaluation (CDE) has received a marketing approval application for Innovent Biologics...
Innovent Biologics’ Pemazyre Becomes First FGFR2 Inhibitor Approved in China
China-based Innovent Biologics Inc. (HKG: 1801) announced that the first prescription has been filled in...
Global Cord Blood Corp’s Cellenkos Gets FDA Nod for Myelofibrosis Trial
Global Cord Blood Corporation (GCBC; NYSE: CO) announced receiving Investigational New Drug (IND) approval from...